Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring.
Seguro FS, Silva CMPDC, Moura CMB, Conchon M, Fogliatto L, Funke VAM, Abdo A, Macedo AVS, Santos MHHD, Saraiva JFK. Seguro FS, et al. Among authors: fogliatto l. Hematol Transfus Cell Ther. 2021 Apr-Jun;43(2):191-200. doi: 10.1016/j.htct.2020.04.009. Epub 2020 Jul 1. Hematol Transfus Cell Ther. 2021. PMID: 32631809 Free PMC article. Review.
BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival.
Pagnano KB, Bendit I, Boquimpani C, De Souza CA, Miranda EC, Zalcberg I, Larripa I, Nardinelli L, Silveira RA, Fogliatto L, Spector N, Funke V, Pasquini R, Hungria V, Sérgio Chiattone C, Clementino N, Conchon M, Moiraghi EB, Lopez JL, Pavlovsky C, Pavlovsky MA, Cervera EE, Meillon LA, Simões B, Hamerschlak N, Bozzano AH, Mayta E, Cortes J, Bengió 5 On Behalf Of Latin American Leukemia Net Lalnet RM. Pagnano KB, et al. Among authors: fogliatto l. Cancer Invest. 2015 Aug 17. Online ahead of print. Cancer Invest. 2015. PMID: 26279306
BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival.
Pagnano KB, Bendit I, Boquimpani C, De Souza CA, Miranda EC, Zalcberg I, Larripa I, Nardinelli L, Silveira RA, Fogliatto L, Spector N, Funke V, Pasquini R, Hungria V, Chiattone CS, Clementino N, Conchon M, Moiraghi EB, Lopez JL, Pavlovsky C, Pavlovsky MA, Cervera EE, Meillon LA, Simões B, Hamerschlak N, Bozzano AH, Mayta E, Cortes J, Bengió RM; Latin American Leukemia Net (LALNET). Pagnano KB, et al. Among authors: fogliatto l. Cancer Invest. 2015;33(9):451-8. doi: 10.3109/07357907.2015.1065499. Epub 2015 Aug 17. Cancer Invest. 2015. PMID: 26288116
[No title available]
[No authors listed] [No authors listed] PMID: 36163925
Characterization of Patients with Chronic Myeloid Leukemia Unresponsive to Tyrosine Kinase Inhibitors Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation.
Carvalho FR, Zuckermann J, Paz A, Fischer G, Daudt LE, Rigoni LD, Silla L, Fogliatto L, de Castro SM, Pilger DA. Carvalho FR, et al. Among authors: fogliatto l. Int J Hematol Oncol Stem Cell Res. 2017 Jan 1;11(1):30-36. Int J Hematol Oncol Stem Cell Res. 2017. PMID: 28286612 Free PMC article.
First report of imatinib measurement in hair: Method development and preliminary evaluation of the relation between hair and plasma concentrations with therapeutic response in chronic myeloid leukemia.
Capron A, Antunes MV, Wagner SC, Mattevi VS, Vieira N, Leite R, Reginato F, Capra M, Fogliatto L, Wallemacq P, Linden R. Capron A, et al. Among authors: fogliatto l. Clin Chim Acta. 2016 Jan 30;453:42-7. doi: 10.1016/j.cca.2015.11.032. Epub 2015 Dec 3. Clin Chim Acta. 2016. PMID: 26657979
47 results